Abstract: Provided is a plant having a desired phenotype and/or desired stress resistance. Provided is a transgenic plant overexpressing a polypeptide that has the activity to control plant morphology or the activity to enhance the environmental stress resistance of plants, wherein the polypeptide(s) is one polypeptide or are a plurality of polypeptides selected from among polypeptides comprising the amino acid sequences represented by SEQ ID NOS: 1-317.

Abstract: An ESD protection device includes a ceramic base material, a pair of opposed electrodes provided on a surface of or in the ceramic base material, and a discharge auxiliary electrode film arranged to connect the pair of opposed electrodes, wherein the discharge auxiliary electrode film is composed of a material containing, as its main constituents, metallic particles and glass covering the metallic particles. The discharge auxiliary electrode film is formed by providing an electrode paste containing glass-coated metallic particles that have an approximately 15% rate of increase in weight at about 400° C. for about 2 hours in air, a resin binder, and a solvent so as to connect the pair of opposed electrodes to each other, and then firing at a temperature of about 600° C. or more, higher than a softening point of glass of the glass-coated metallic particles, and not +200° C. higher than the softening point.

Abstract: An ESD protection device includes a ceramic base material, a pair of opposed electrodes provided on a surface of or in the ceramic base material, and a discharge auxiliary electrode film arranged to connect the pair of opposed electrodes, wherein the discharge auxiliary electrode film is composed of a material containing, as its main constituents, metallic particles and glass covering the metallic particles. The discharge auxiliary electrode film is formed by providing an electrode paste containing glass-coated metallic particles that have an approximately 15% rate of increase in weight at about 400° C. for about 2 hours in air, a resin binder, and a solvent so as to connect the pair of opposed electrodes to each other, and then firing at a temperature of about 600° C. or more, higher than a softening point of glass of the glass-coated metallic particles, and not +200° C. higher than the softening point.

Abstract: A method of evaluating the flame retardancy of a sealing resin comprises a step of fusion cutting a heating element by causing the heating element to generate heat by the passage of electric current to a test sample of a molded body of the sealing resin including the heating element therein; a step of igniting the sealing resin by continuing the passage of electric current even after the heating element is fusion-cut; and a step of measuring voltage and/or current applied in a period from when the heating element is fusion-cut to the ignition of the sealing resin. The test sample is used in the method of evaluating the flame retardancy and provided with a heating wire; conducting terminals made of metal having an electric resistance lower than the heating wire and connected to both ends of the heating wire; and a sealing resin layer covering the outer periphery of the heating wire.

Abstract: The present invention relates to a novel fatty acid derivative of the following formula: ##STR1## wherein R.sup.1 is acyl group, etc.;R.sup.2 is acyl(lower)alkyl;R.sup.3 is lower alkyl, etc.;R.sup.4 is hydrogen, etc.; andX is --O--, etc;and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said fatty acid derivative or a salt thereof; a pharmaceutical composition comprising said fatty acid derivative or a pharmaceutically acceptable salt thereof; etc.

Abstract: A new FR901451 substance which is produced by culturing a FR901451 substance-producing strain of the genus Flexibacter in a nutrient medium, this new substance possessing a human leukocyte elastase-inhibiting activity.

Abstract: A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.

Abstract: WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.

Abstract: A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.

Abstract: A method of treating pulmonary emphysema or adult respiratory distress syndrome in a subject in need thereof which comprises administering to the subject an effective amount of WS7622A, B, C and/or D, derivatives thereof, or their pharmaceutically acceptable salt.

Abstract: Pyrroline compounds of the formulae (I) and (II) are effective in the treatment of retroviral infection and lymphadenopathy.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each lower alkyl, R.sup.4 is hydrogen or hydroxy, and a heavy solid line means a double bond when R.sup.4 is hydrogen and a single bond when R.sup.4 is hydroxy is useful in the treatment of diseases caused by reactive oxygen species and organic radicals.

Abstract: The present invention relates to new WS7622A, B, C and/or D substances, derivatives thereof and pharmaceutical compositions containing the new substances as active ingredients.

Abstract: The invention relates to a compound of antimicrobial activity of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkanoyl,R.sup.2 is hydrogen or ##STR2## in which R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen or lower alkanoyl,R.sup.3 is carboxy or a protected carboxy, and pharmaceutically acceptable salt thereof.

Abstract: New nitro aliphatic compounds useful as antithrombotic and antihypertensing agents are disclosed.

Abstract: The invention relates to novel furanone derivatives, having an aldose reductase-inhibitory activity, of the formula ##STR1## wherein A is a lower alkylene group,R.sup.1 is a carboxy, hydroxy, protected hydroxy or lower alkoxycarbonyl group,R.sup.2 is a hydrogen or halogen atom or a halo (lower) alkyl group, andR.sup.3 is a hydrogen atom or a hydroxy, carboxy, lower alkoxy or lower alkoxycarbonyl group.

Abstract: The invention relates to compounds of antihypertensive and antithrombotic activity of the formula or its pharmaceutically acceptable salt: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyphenyl,R.sup.2 is hydrogen or lower alkyl,R.sup.4 is lower alkyl,R.sup.6 is hydrogen or lower alkyl,R.sup.7 is lower alkyl which is optionally substituted by hydroxy or lower alkanoyloxy, andR.sup.10 is hydrogen or lower alkyl which is optionally substituted by carboxy or esterified carboxy.

Abstract: New nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: New Nitro aliphatic compounds and their pharmaceutically acceptable salts are disclosed.

Abstract: Described are compounds of the formula: ##STR1## Wherein A is a lower alkylene group;R.sup.1 is a carboxy, hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino, phenyl(lower)alkyloxy, benzoyloxy or lower alkanoyloxy group;R.sup.2 is a hydrogen or halogen atom or a halo(lower)alkyl group;R.sup.3 is a hydrogen or halogen atom;R.sup.4 is hydroxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group; andR.sup.5 is a hydrogen or halogen atom;Q is the number of double bonds which is equal to 0 or 1;n is an integer of 0 or 1, provided that when Q is 0, n is 1 and when Q is 1, n is 0.